Background
==========

Over the past 20 years, many strains of *Plasmodium falciparum*have become resistant to chloroquine and other anti-malarial drugs \[[@B1]\]. Since 2001, more than 60 countries have officially adopted artemisinin-based combination therapies (ACTs) for the treatment of falciparum malaria \[[@B2],[@B3]\]. However, clinical failures or at least longer parasite clearance times with ACT have been described in Cambodia \[[@B4]-[@B7]\]. The emergence and spread of resistance to most of the anti-malarial drugs require intensive research into identifying molecular markers of resistance, as well as implementing *in vitro*and *in vivo*surveillance programmes, such as those supported by the Worldwide Antimalarial Resistance Network \[[@B8],[@B9]\].

There are basically three approaches to assess anti-malarial drug susceptibility of *P. falciparum*: assessment of therapeutic efficacy standardized by the World Health Organization (WHO) \[[@B10]\], *in vitro*assays and molecular markers of resistance.

In a number of laboratories surveying anti-malarial drug resistance, *in vitro*tests are performed using the uptake of a radiolabelled nucleic acid precursor \[^3^H\]-hypoxanthine as a marker of parasite growth \[[@B11]\]. Other non-radioactive methods can be used: the WHO schizont maturation test by optical microscopy (Mark III) with pre-dosed plates \[[@B12]\], which was based on the methods of Rieckmann *et al*\[[@B13]\] and Wernsdorfer \[[@B14]\], a flow cytometric analysis of propidium iodide incorporation into parasite, which permits a stage-specific evaluation of anti-malarial compounds \[[@B15]\], a fluorescent-based technique that uses SYBR green I which binds to DNA \[[@B16],[@B17]\], and colorimetric or enzyme-linked immunosorbent assays (ELISA) to measure histidine-rich protein II (HRP2) \[[@B18],[@B19]\] or plasmodial lactate dehydrogenase enzyme (pLDH) \[[@B20],[@B21]\].

Many factors induce high variations in *P. falciparum*growth and 50% inhibitory concentration (IC~50~) values and influence the results of the chemosusceptibility tests \[[@B22]\], such as culture medium, initial parasitaemia, haematocrit, incubation time, time point when \[^3^H\]-hypoxanthine is added, use of serum substitutes, storage conditions of sample, delay before cultivation of samples and atmosphere (gas mixtures).

Laboratories using isotopic microtest to monitor drug resistance work at different oxygen tensions: 3% O~2~\[[@B15]\], 5% O~2~\[[@B18],[@B19]\], 10% O~2~\[[@B23],[@B24]\], in candle jars \[[@B20],[@B25]\] (which corresponds to approximately 17-18% O~2~) and \>20% O~2~\[[@B21],[@B22]\] (in CO~2~incubators). WHO recommends the use of a candle jar in their *in vitro*microtests (Mark III). Despite the varying culture conditions, many laboratories have adopted the same threshold for the resistance to anti-malarial compounds under different oxygen tensions. For example, our previous study has shown that the chloroquine IC~50~values at 10% O~2~were significantly higher than those at 21% O~2~\[[@B26]\]. Nevertheless, it seems that O~2~concentrations between 1% and 17.5% do not affect the IC~50~values of quinoline-containing anti-malarial drugs \[[@B27]-[@B29]\]. In contrast, the *in vitro*anti-malarial activity of some antibiotics was dependent on the O~2~concentration \[[@B27]\].

The aim of this study was to evaluate a cultivation system in which the proper conditions of atmosphere for growing *P. falciparum*parasites were maintained in an air-tight sealed bag. The Genbag^®^system was initially designed as atmospheric generators for capnophilic bacteria. Genbag CO2^®^(BioMérieux;Marcy l\'Etoile, France) was used for *in vitro*susceptibility test of nine standard anti-malarial drugs, and the IC~50~s were compared to those obtained with controlled incubator conditions (5% CO~2~, 10% O~2~and 85% N~2~).

Methods
=======

Strains of *P. falciparum*
--------------------------

A total of 36 pre-identified parasite strains (well-characterized laboratory strains or strains obtained from isolates after growth in culture for an extended period of time) from a wide panel of countries were maintained in culture in RPMI 1640 (Invitrogen, Paisley, United Kingdom), supplemented with 10% human serum (Abcys S.A., Paris, France) and buffered with 25 mM HEPES and 25 mM NaHCO~3~. Parasites were grown in type A^+^human red blood cells under controlled atmospheric conditions that consisted of 10% O~2~, 5% CO~2~and 85% N~2~at 37°C with a relative humidity of 95%. All strains were synchronized twice with sorbitol before use \[[@B30]\]. Clonality was verified using PCR genotyping of polymorphic genetic markers *msp1*, *msp2*, and microsatellite loci \[[@B31],[@B32]\]. Chloroquine-susceptible 3D7 clone and chloroquine-resistant W2 clone (MR4 Resource Center) were cultivated in the same conditions and assessed for drug susceptibility in 4 independent experiments.

Drugs
-----

Chloroquine, quinine, dihydroartemisinin, pyrimethamine and doxycycline were purchased from Sigma (Saint Louis, MO). Monodesethylamodiaquine was obtained from the WHO (Geneva, Switzerland). Mefloquine was obtained from Roche (Paris, France). Lumefantrine was provided by Novartis Pharma (Basel, Switzerland), and atovaquone was from GlaxoSmithKline (Evreux, France). Chloroquine and pyrimethamine were dissolved and diluted in water to obtain final concentrations ranging from 5 to 3,200 nM for chloroquine and 5 to 40,000 nM for pyrimethamine. Quinine, monodesethylamodiaquine, mefloquine, dihydroartemisinin, atovaquone and doxycycline were first dissolved in methanol and then diluted in water to obtain final concentrations ranging from 5 to 3,200 nM for quinine, 1.56 to 1000 nM for monodesethylamodiaquine, 3.2 to 400 nM for mefloquine, 0.1 to 100 nM for dihydroartemisinin, 0.3 to 100 nM for atovaquone and 0.1 to 502 μM for doxycycline. Lumefantrine was dissolved and diluted in ethanol to obtain final concentrations ranging from 0.5 to 310 nM.

In vitro assay
--------------

For *in vitro*isotopic microtests, 200 μL/well of a suspension of synchronous parasitized red blood cells (final parasitaemia, 0.5%; final haematocrit, 1.5%) was distributed in 96-well plates predosed with anti-malarial drugs. Parasite growth was assessed by adding 1 μCi of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin-Elmer, Courtaboeuf, France) to each well at time zero. The plates were incubated for 42 h at 37°C in controlled atmospheric conditions in incubator (5% CO~2~, 10% O~2~and 85% N~2~) and Genbag^®^with the atmospheric generators for capnophilic bacteria Genbag CO2^®^(two plates per sealed bag) (Figure [1](#F1){ref-type="fig"}). Immediately after incubation, plates were frozen and then thawed to lyse the erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin-Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin-Elmer). The filter microplates were dried, and 25 μL of scintillation cocktail (Microscint O; Perkin-Elmer) were placed in each well. The radioactivity incorporated into the nucleotides of the parasites was measured with a scintillation counter (Top Count; Perkin-Elmer).

![**The Genbag^®^system associated with the atmospheric generators for capnophilic bacteria Genbag CO2^®^with 2 plates in the specific sealed bag (picture P Millileri)**.](1475-2875-10-8-1){#F1}

The drug concentration that inhibits 50% of parasite growth (IC~50~) was designated as the concentration at which the tritiated hypoxanthine incorporation reached 50% of the total incorporation by the parasites in the drug-free control wells. The IC~50~value was determined by non-linear regression analysis of log-based dose-response curves (Riasmart, Packard, Meriden, USA).

Statistical analysis
--------------------

Count per minute (cpm) and IC~50~were expressed as geometric means and 95% confidence intervals. The differences between the data observed in the incubator and Genbag^®^were analysed by a paired *t*-test. The correlation between the responses under two incubation conditions for each anti-malarial drug was estimated by the Pearson correlation coefficient R. The same analyses were performed on IC~50~strains/IC~50~3D7 or IC~50~strains/IC~50~W2 ratios calculated for each anti-malarial drug under the two conditions.

Results
=======

A total of 1,098 drug-free control wells were analysed for each experimental condition. A significant difference was observed in the tritiated hypoxanthine uptake between the two conditions with 36 strains of *P. falciparum*(Table [1](#T1){ref-type="table"}). The mean cpm values in the control wells under the controlled incubator conditions (5% CO~2~and 10% O~2~) were significantly higher than those under Genbag^®^conditions (2738 vs 2282 cpm, p value \< 0.0001).

###### 

In vitro activity of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O~2~) and Genbag^®^conditions (15% O~2~)

  Compound                  **O**~**2**~**%**   **IC**~**50**~   t-test p-value                  
  ------------------------- ------------------- ---------------- ---------------- ------ ------- ----------
  Chloroquine               10                  127 nM           77-211           8      1032    \<0.0001
                            15                  94 nM            61-146           12     751     
  Quinine                   10                  580 nM           451-745          153    1752    \<0.0001
                            15                  439 nM           336-573          96     1288    
  Mefloquine                10                  57.5 nM          50.7-65.3        30.8   131.0   0.0011
                            15                  49.7 nM          44.0-46.3        26.4   113.0   
  Monodesethylamodiaquine   10                  41.4 nM          28.8-59.6        4.7    379     \<0.0001
                            15                  31.8 nM          21.8646.2        4.0    357     
  Lumefantrine              10                  23.8 nM          19.6628.8        7.1    65.0    0.0044
                            15                  21.2 nM          17.5-25.7        7.2    72      
  Pyrimethamine             10                  273 nM           88-852           10     17025   0.0902
                            15                  222 nM           67-735           10     14938   
  Atovaquone                10                  1.2 nM           0.8-1.8          0.1    7.3     0.0011
                            15                  2.1 nM           1.6-2.8          0.2    11.7    
  Dihydroartemisinin        10                  2.4 nM           2.0-2.9          1.2    10.8    0.4088
                            15                  2.4 nM           1.9-2.9          1.0    14.3    
  Doxycycline               10                  10.9 μM          9.8-12.1         7.6    26.0    0.6771
                            15                  10.8 μM          9.5-12.2         6.3    24.5    
  cpm                       10                  2738             2628-2852        671    17845   \<0.0001
                            15                  2282             2189-2379        623    12726   

Compared to Genbag^®^conditions (5% CO~2~and 15% O~2~), the geometric mean IC~50~estimated under the incubator atmospheric conditions (5% CO~2~and 10% O~2~) was significantly lower for atovaquone (1.2 vs 2.1 nM, p = 0.0011) and higher for the quinolines: chloroquine (127 vs 94 nM, p \< 0.0001), quinine (580 vs 439 nM, p \< 0.0001), monodesethylamodiaquine (41.4 vs 31.8 nM, p \< 0.0001), mefloquine (57.5 vs 49.7 nM, p = 0.0011) and lumefantrine (23.8 vs 21.2 nM, p = 0.0044) (Table [1](#T1){ref-type="table"}). There was no significant difference of IC~50~between the two conditions for dihydroartemisinin, doxycycline and pyrimethamine.

The cpm and IC~50~values for each anti-malarial drug were highly and significantly correlated between the two conditions (Figure [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![**Correlation between log IC**~**50**~**values of chloroquine, quinine or mefloquine, against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O**~**2**~**) and Genbag^®^conditions (15% O**~**2**~**)**.](1475-2875-10-8-2){#F2}

![**Correlation between log IC**~**50**~**values of monodesethylamodiaquine, lumefantrine or pyrimethamine against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O**~**2**~**) and Genbag^®^conditions (15% O**~**2**~**)**.](1475-2875-10-8-3){#F3}

![**Correlation between log IC**~**50**~**values of atovaquone, dihydroartemisinin or doxycycline against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O**~**2**~**) and Genbag^®^conditions (15% O**~**2**~**)**.](1475-2875-10-8-4){#F4}

Based on the thresholds of decreased susceptibility defined for the incubator atmospheric conditions (5% CO~2~and 10% O~2~), the following discrepancies were observed: one of 21 strains (5%) with IC~50~\>100 nM for chloroquine \[[@B33]\] was \<100 nM under Genbag^®^conditions; seven of 20 strains (35%) with IC~50~\>800 nM for quinine \[[@B34]\] was \<800 nM under Genbag^®^conditions; two of 20 strains (10%) with IC~50~\>30 nM for mefloquine \[[@B35]\] was \<30 nM under Genbag^®^conditions; four of 10 strains (40%) with IC~50~\>80 nM for monodesethylamodiaquine \[[@B36]\] was \<80 nM under Genbag^®^conditions; and none of the 13 strains with IC~50~\>2,000 nM for pyrimethamine \[[@B37]\] was \< 2,000 nM under Genbag^®^conditions.

To reduce this difference in terms of anti-malarial susceptibility, a specific cut-off was estimated for each drug under Genbag^®^conditions by regression. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O~2~), 611 nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM) and 1729 nM for pyrimethamine (vs 2,000 nM). The cut-off was not re-estimated for drugs for which all the CI~50~values were below the cut-off under controlled incubation conditions. For these drugs, median values were estimated: 2.9 nM for atovaquone (vs 2.5 nM in 10% O~2~), 26 nM for lumefantrine (vs 30 nM), 3 nM for dihydroartemisinin (vs 3.0 nM) and 15 μM for doxycycline (vs 15 μM).

The geometric mean ratio based on the chloroquine-susceptible reference clone 3D7 (strain IC~50~/3D7 IC~50~) obtained under the incubator atmospheric conditions (5% CO~2~and 10% O~2~) was significantly higher for chloroquine (p \< 0.0001), lumefantrine (p = 0.0119), and dihydroartemisinin (p = 0.0006), but the ratio was significantly lower for mefloquine (p \< 0.0001) and doxycycline (p = 0.0002) (Table [2](#T2){ref-type="table"}). The geometric mean ratio based on the chloroquine-resistant reference clone W2 (strain IC~50~/W2 IC~50~) obtained under the incubator atmospheric conditions (5% CO~2~and 10% O~2~) was significantly higher for chloroquine (p = 0.0014), quinine (p = 0.0006), monodesethylamodiaquine (p \< 0.0001), lumefantrine (p \< 0.0001), pyrimethamine (p = 0.0026) and was significantly lower for dihydroartemisinin (p \< 0.0001) and doxycycline (p = 0.0159) (Table [3](#T3){ref-type="table"}).

###### 

Ratio based on the chloroquine-susceptible reference clone 3D7 (strain IC~50~/3D7 IC~50~) of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O~2~) and Genbag^®^conditions (15% O~2~)

  Compound                  **O**~**2**~**%**   **IC**~**50**~**/3D7 IC**~**50**~   t-test p-value                  
  ------------------------- ------------------- ----------------------------------- ---------------- ------ ------- ----------
  Chloroquine               10                  6.88                                4.15-11.41       0.40   55.80   \<0.0001
                            15                  4.80                                3.09-7.45        0.60   38.30   
  Quinine                   10                  2.44                                1.90-3.13        0.65   7.39    0.2418
                            15                  2.63                                2.04-3.40        0.66   7.24    
  Mefloquine                10                  0.72                                0.63-0.82        0.39   1.64    \<0.0001
                            15                  0.91                                0.81-1.03        0.49   2.089   
  Monodesethylamodiaquine   10                  2.59                                1.80-3.72        0.29   23.69   0.5948
                            15                  2.52                                1.73-3.67        0.32   28.33   
  Lumefantrine              10                  0.90                                0.74-1.09        0.27   2.45    0.0119
                            15                  0.81                                0.67-0.98        0.28   2.76    
  Pyrimethamine             10                  27.31                               8.75-85.21       1.00   1703    0.0835
                            15                  18.01                               5.51-58.82       1.00   1494    
  Atovaquone                10                  0.88                                0.59-1.31        0.07   5.20    0.9187
                            15                  0.89                                0.67-1.19        0.08   4.96    
  Dihydroartemisinin        10                  1.53                                1.27-1.85        0.74   6.79    0.0006
                            15                  1.31                                1.04-1.64        0.54   7.94    
  Doxycycline               10                  1.21                                1.09-1.35        0.85   2.90    0.0002
                            15                  1.37                                1.21-1.55        0.80   3.11    

###### 

Ratio based on the chloroquine-resistant reference clone W2 (strain IC~50~/W2 IC~50~) of chloroquine, quinine, mefloquine, monodesethylamodiaquine, lumefantrine, pyrimethamine, atovaquone, dihydroartemisinin and doxycycline against 36 strains of *Plasmodium falciparum*under controlled incubator conditions (10% O~2~) and Genbag^®^conditions (15% O~2~)

  Compound                  **O**~**2**~**%**   **IC**~**50**~**/W2 IC**~**50**~   t-test p-value                   
  ------------------------- ------------------- ---------------------------------- ---------------- -------- ------ ----------
  Chloroquine               10                  0.26                               0.16-0.43        0.02     2.12   0.0014
                            15                  0.21                               0.14-0.33        0.03     1.71   
  Quinine                   10                  0.71                               0.56-0.90        0.19     2.04   0.0006
                            15                  0.56                               0.43-0.74        0.12     1.65   
  Mefloquine                10                  0.97                               0.66-1.42        0.43     1.82   0.6262
                            15                  0.82                               0.72-0.92        0.43     1.85   
  Monodesethylamodiaquine   10                  0.49                               0.34-0.70        0.06     4.47   \<0.0001
                            15                  0.37                               0.25-0.54        0.05     4.14   
  Lumefantrine              10                  1.25                               1.03-1.52        0.37     3.42   \<0.0001
                            15                  0.94                               0.78-1.15        0.32     3.21   
  Pyrimethamine             10                  0.03                               0.01-0.10        0.001    1.96   0.0026
                            15                  0.02                               0.01-0.07        0.0008   1.26   
  Atovaquone                10                  0.65                               0.44-0.97        0.05     3.85   0.8646
                            15                  0.67                               0.50-0.89        0.06     3.71   
  Dihydroartemisinin        10                  1.06                               0.88-1.28        0.51     4.70   \<0.0001
                            15                  1.55                               1.24-1.94        0.65     9.41   
  Doxycycline               10                  1.16                               1.05-1.29        0.81     2.78   0.0159
                            15                  1.25                               11.10-1.42       0.73     2.85   

Discussion
==========

The first works that assessed oxygen effects on *P. falciparum*asynchronous cultures had shown that microaerophilic environment allowed an optimal development of parasites \[[@B38]\]. Parasite growth failed under strict anaerobic conditions. *Plasmodium falciparum*possesses a functional mitochondrial respiratory chain with oxygen consumption \[[@B39]\]. It has been shown that there is some protector effect of CO~2~at high oxygen concentration \[[@B38]\] through the medium pH, the stability (between 7.2 and 7.45) of which is required for parasite growth \[[@B40]\]. The standard medium RPMI 1640, buffered with 25 mM HEPES and 25 mM NaHCO~3~, was optimized to maintain the pH within the physiological range in an atmosphere containing 5% CO~2~. Any modification of the CO~2~concentration alters the pH of the medium, which in turn can influence the IC~50~values of pH-dependent drugs, such as quinolines, but not of those that are pH-independent, such as pyrimethamine. Despite similar growth and tritium-labelled hypoxanthine incorporation rates in drug-free control wells, Shenyi He *et al*showed that increasing the CO~2~concentration from 2.7% to 7% (with a constant 5% O~2~) resulted in significantly higher chloroquine IC~50~values \[[@B29]\]. The chloroquine-resistant K1 strain showed nine-fold greater chloroquine IC~50~when the CO~2~concentration was increased from 2.7 to 7% \[[@B29]\].

The atmospheric generators for capnophilic bacteria Genbag CO~2~^®^evaluated in this study release about 5% CO~2~and reduce to 15% O~2~in 30 min, according to the manufacturer\'s specifications (<http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?doc=CNL_PRD_CPL_G_PRD_CLN_62>). The stated conditions are maintained at least for 48 h. In this context, it seems that the significant differences in drug IC~50~values and growth level (cpm) between the two conditions, the incubator atmospheric conditions (5% CO~2~and 10% O~2~) and the Genbag^®^conditions (5% CO~2~and 15% O~2~), are due to the difference in O~2~concentration.

The IC~50~values of quinoline drugs, such as chloroquine, quinine, monodesethylamodiaquine, mefloquine and lumefantrine were significantly lower at 15% O~2~(Genbag CO~2~^®^) than those at 10% O~2~(the incubator atmospheric conditions). This is in agreement with the previous results that showed in 136 *P. falciparum*fresh isolates from Comoros that the chloroquine IC~50~values at 10% O~2~were significantly higher than those at 21% O~2~, with the means of 173.5 nM and 121.5 nM, respectively \[[@B26]\]. Of particular interest among the 63 isolates that were resistant *in vitro*to chloroquine (IC~50~\>100 nM) at 5% CO~2~and 10% O~2~, was the observation that 17 were susceptible to chloroquine (IC~50~\< 100 nM) at 21% O~2~\[[@B26]\]. In the present study, only one of 21 strains with chloroquine IC~50~\>100 nM at 10% O~2~had IC~50~\< 100 nM at a concentration of 15%. Some studies failed to show oxygen-dependent effects of chloroquine on *P. falciparum*in culture \[[@B27]-[@B29]\], but in these experiments less than four strains were tested. Shenyi He *et al*reported that the chloroquine IC~50~values determined in a candle jar (2.7% CO~2~and 17.5% O~2~) were similar to those determined in an incubator set at 2.7% CO~2~and 5% O~2~\[[@B27]\]. Lin *et al*observed similar chloroquine IC~50~values with parasites incubated in 5% CO~2~and 5% or 15% O~2~generated by an AnaeroPack system \[[@B29]\].

In contrast, there was no significant difference of IC~50~values between 10% and 15% O~2~conditions for doxycycline, dihydroartemisinin and pyrimethamine. Divo *et al*. reported that the anti-malarial activity of different cyclines was O~2~-dependent and higher at high O~2~concentrations \[[@B27]\]. Nevertheless, this influence of O~2~was not evident at 48 h but was profound at 96 h. In the present study, IC~50~values were only determined at 42 h. The class of artemisinins contains an intramolecular peroxide bridge that is situated in the sesquiterperne lactone backbone structure. The anti-malarial potency of artemisinin was enhanced by oxygen and inhibited by oxygen radical scavengers \[[@B41],[@B42]\]. The contrast between 10 and 15% O~2~is probably not high enough to observe any difference in dihydroartemisinin IC~50~values.

Using the threshold values for in vitro resistance established under the controlled incubator conditions (5% CO~2~and 10% O~2~), 0 - 40% of discordant results, depending on the test compounds, was obtained using the Genbag^®^incubation system. The effect of gas mixture on the results of chemosusceptibility assay should lead different laboratories involved in anti-malarial resistance survey to adapt a resistance threshold for each gas mixture or to use the same conditions to perform chemosusceptibility microtests. The cut-off value was re-estimated for each drug in Genbag^®^conditions. The cut-off was estimated at 77 nM for chloroquine (vs 100 nM in 10% O~2~), 611 nM for quinine (vs 800 nM), 30 nM for mefloquine (vs 30 nM), 61 nM for monodesethylamodiaquine (vs 80 nM) and 1729 nM for pyrimethamine (vs 2000 nM).

To reduce the effects of O~2~on IC~50~values between 10 and 15% O~2~, the ratios of strain IC~50~/3D7 IC~50~and strain IC~50~/W2 IC~50~were calculated for each condition. Nevertheless, the mean ratios were not similar at 10% and 15% O~2~for most anti-malarial drugs, and the results depended on the reference clone.

Conclusions
===========

The atmospheric generators for capnophilic bacteria Genbag CO2^®^is an appropriate technology that can be transferred to the field for epidemiological surveys of drug-resistant malaria. The present data suggest the importance of the gas mixture on *in vitro*microtest results for anti-malarial drugs and the importance of determining the microtest conditions before comparing and analysing the data from different laboratories and concluding on malaria resistance.
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